Celcuity (CELC) Depreciation & Amortization (CF) (2016 - 2025)
Celcuity's (CELC) quarterly Depreciation & Amortization (CF) came in at $49000.0 in Q4 2025, up 40.0% YoY from $35000.0 in Q4 2024, and up 19.51% on a QoQ basis from $41000.0 in Q3 2025.
Celcuity (CELC) Depreciation & Amortization (CF) (2016 - 2025) Analysis & Trends
Celcuity (CELC) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $49000.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 40.0% year-over-year to $49000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $167000.0 (up 28.46% YoY) and the FY2025 annual result came in at $167000.0, up 28.46% from the prior year.
- Depreciation & Amortization (CF) advanced to $49000.0 in Q4 2025, from $41000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $98222.0 in Q1 2021 to a low of $27948.0 in Q4 2023.
- A 5-year average of $47696.2 and a median of $42469.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) slumped 43.0% — and 2025, when it jumped 40.0%.
- Tracing CELC's Depreciation & Amortization (CF) over 5 years: stood at $63029.0 in 2021, then retreated by 22.36% to $48937.0 in 2022, then tumbled by 42.89% to $27948.0 in 2023, then climbed by 25.23% to $35000.0 in 2024, then jumped by 40.0% to $49000.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $49000.0 (Q4 2025), $41000.0 (Q3 2025), and $40000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Mar 31, 2025 | 37,000.00 |
| Mar 31, 2025 | 37,000.00 |
| Dec 31, 2024 | 35,000.00 |
| Dec 31, 2024 | 35,000.00 |
| Sep 30, 2024 | 34,000.00 |
| Sep 30, 2024 | 34,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 27,948.00 |
| Dec 31, 2023 | 27,948.00 |
| Sep 30, 2023 | 33,555.00 |
| Sep 30, 2023 | 33,555.00 |